The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Alabama has moved up the most recent obesity rankings from U.S. News & World Report. And we’re getting awfully close to the ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrates positive ...

A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

The strategy of rewiring the brain's stress response is rooted in two pieces of scientific literature. One is biochemical.

A new study shows that people who develop type 1 diabetes in adulthood have an increased risk of cardiovascular disease and death, and that those diagnosed later in life do not have a better prognosis ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.